EIF2AK3 and diffuse large B-cell lymphoma: There was a statistical significance in ITPR1 (P = 0.0242) and EIF2AK3 (P = 0.0459) expression among patients with stage I, II, III, or IV DLBCL (Supplementary Figure 2D).